10779/rcsi.10766786.v1 Lauren E. Mulcahy Lauren E. Mulcahy Caroline M. Curtin Caroline M. Curtin Ryan J. McCoy Ryan J. McCoy Fergal O'Brien Fergal O'Brien David Taylor David Taylor T Clive Lee T Clive Lee Garry P. Duffy Garry P. Duffy The effect of bisphosphonate treatment on the biochemical and cellular events during bone remodelling in response to microinjury stimulation. Royal College of Surgeons in Ireland 2019 Animals Bone Density Conservation Agents Bone Remodeling Bone and Bones Diphosphonates Imidazoles Mice Osteoblasts Osteoclasts Osteocytes Osteogenesis Osteoporosis Anatomy 2019-11-22 15:13:23 Journal contribution https://repository.rcsi.com/articles/journal_contribution/The_effect_of_bisphosphonate_treatment_on_the_biochemical_and_cellular_events_during_bone_remodelling_in_response_to_microinjury_stimulation_/10766786 <p>Osteoporosis is one of the most prevalent bone diseases worldwide and is characterised by high levels of bone turnover, a marked loss in bone mass and accumulation of microdamage, which leads to an increased fracture incidence that places a huge burden on global health care systems. Bisphosphonates have been used to treat osteoporosis and have shown great success in conserving bone mass and reducing fracture incidence. In spite of the existing knowledge of the in vivo responses of bone to bisphosphonates, the cellular responses to these drugs have yet to be fully elucidated. In vitro model systems that allow the decoupling of complex highly integrated events, such as bone remodelling, provide a tool whereby these biological processes may be studied in a more simplified context. This study firstly utilised an in vitro model system of bone remodelling and comprising all three major cell types of the bone (osteocytes, osteoclasts and osteoblasts), which was representative of the bone's capacity to sense microdamage and subsequently initiate a basic multicellular unit response. Secondly, this system was used to study the effect of two commonly utilised aminobisphosphonate treatments for osteoporosis, alendronate and zoledronate. We demonstrated that microinjury to osteocyte networks being treated with bisphosphonates modulates receptor activator of nuclear factor kappa-B ligand and osteoprotegerin activity, and subsequently osteoclastogenesis. Furthermore, bisphosphonates increased the osteogenic potential following microinjury. Thus, we have shown for the first time that bisphosphonates act at all three stages of bone remodelling, from microinjury to osteoclastogenesis and ultimately osteogenesis.</p>